• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Pheton Holdings Ltd

    11/28/25 1:05:11 PM ET
    $PTHL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $PTHL alert in real time by email
    6-K 1 ea0267647-6k_pheton.htm REPORT OF FOREIGN PRIVATE ISSUER

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER
    PURSUANT TO RULE 13a-16 OR 15d-16
    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    For the month of November 2025

     

    Commission File Number: 001-42263

     

    Pheton Holdings Ltd

     

    Room 306, NET Building

    Hong Jun Ying South Road, Chaoyang District

    Beijing, China

    (Address of Principal Executive Office)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

     

    Form 20-F ☒       Form 40-F ☐

     

     

     

     

     

     

    Changes in Company’s Certifying Accountant

     

    On November 28, 2025, Pheton Holdings Ltd, a Cayman Islands company (the “Company”) terminated engagement of Marcum Asia CPAs LLP (“Marcum”) as the Company’s independent registered public accounting firm. The change was approved by the audit committee of the board of directors of the Company. The Company’s decision to terminate the engagement was not the result of any disagreement between the Company and Marcum on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure.

     

    The principal accountant’s report of Marcum on the financial statements of the Company as of and for the fiscal years ended December 31, 2024, 2023 and 2022 did not contain any adverse opinion or disclaimer of opinion and was not qualified or modified as to uncertainty, audit scope or accounting principles. Marcum was engaged since September 30, 2022.

     

    During the fiscal years ended December 31, 2024, 2023 and 2022 and the subsequent interim period through November 25, 2025, the date of termination of the engagement, (i) there were no “disagreements” (as described in Item 16F(a)(1)(iv) of Form 20-F and the related instructions) between the Company and Marcum on any matter of accounting principles or practices, financial statement disclosure or auditing scope or procedures, which disagreements, if not resolved to Marcum’s satisfaction, would have caused Marcum to make reference to the subject matter of the disagreement(s) in connection with its report to the subject matter of the disagreement; and (ii) there were no “reportable events” of the type described in Item 16F(a)(1)(v) of Form 20-F.

     

    During the audit of the Company’s financial statements as of and for the year ended December 31, 2024, 2023 and 2022, Marcum identified certain material weaknesses in the Company’s internal controls which were: (i) lack of sufficient in-house personnel in our accounting department with sufficient knowledge of the U.S. GAAP and SEC reporting rules; (ii) lack of formal policies and procedures to establish risk assessment processes and an internal control framework; and (iii) lack of information technology general control in the areas of: (a) risk and vulnerability assessment and management, (b) third-party (service organization) vendor management, (c) system change management, (d) backup and recovery management, (e) access to systems and data, (f) segregation of duties, privileged access, and monitoring, (g) password management and (h) cyber security management. These material weaknesses are described in the Company’s annual report on Form 20-F for the fiscal year ended December 31, 2024, which the Company filed on March 20, 2025, with the Securities and Exchange Commission. The Company is in the process of implementing a number of measures to address these material weaknesses identified.

     

    We furnished a copy of the disclosures in this report to Marcum and requested that Marcum furnish us with a letter addressed to the SEC stating whether such firm agrees with the above statements or, if not, stating the respects in which it does not agree. A copy of the letter has been furnished as an exhibit to this report as Exhibit 16.1.

     

    1

     

     

    Exhibits.

     

    Exhibit No.   Description
    16.1   Letter of Marcum Asia CPAs LLP dated November 28, 2025, regarding change in independent registered public accounting firm.

     

    2

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

      Pheton Holdings Ltd
         
    Date: November 28, 2025 By: /s/ Jianfei Zhang
      Name: Jianfei Zhang
      Title: Chief Executive Officer and Chairman of the Board of Directors

     

    3

     

     

     

    Get the next $PTHL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PTHL

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PTHL
    SEC Filings

    View All

    SEC Form 6-K filed by Pheton Holdings Ltd

    6-K - Pheton Holdings Ltd (0001970544) (Filer)

    1/13/26 4:00:30 PM ET
    $PTHL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 6-K filed by Pheton Holdings Ltd

    6-K - Pheton Holdings Ltd (0001970544) (Filer)

    12/22/25 7:43:23 AM ET
    $PTHL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 6-K filed by Pheton Holdings Ltd

    6-K - Pheton Holdings Ltd (0001970544) (Filer)

    12/16/25 12:58:56 PM ET
    $PTHL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $PTHL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Pheton Holdings Ltd Announces Corporate Name Change and Stock Ticker Symbol Change

    BEIJING, China, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pheton Holdings Ltd (the "Company" or "Pheton"), a healthcare solution provider specializing in treatment planning systems for brachytherapy and other related products and services, announced today that it will change its corporate name to iTonic Holdings Ltd, and change its stock ticker symbol to "ITOC" (collectively, the "Corporate Events"). The Company anticipates that the Corporate Events will be effective upon the commencement of trading on the Nasdaq Capital Market on January 16, 2026 (U.S. Eastern Time), at which time the Company's Class A ordinary shares will cease trading under the current ticker symbol "PTHL" and will begin tradi

    1/13/26 8:30:00 AM ET
    $PTHL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Pheton Holdings Ltd Announces Closing of Share Acquisition with iTonic Corporation

    Beijing, China, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Pheton Holdings Ltd (NASDAQ:PTHL) ("Pheton" or the "Company"), a healthcare solution provider specializing in treatment planning systems for brachytherapy and other related products and services, today announced the successful completion of its acquisition of 51% of the total outstanding shares of iTonic Corporation (the "Target"), a U.S.-based integrated home health AI company that combines AI, medical device automation, and easier access to clinical expertise to support continuity of care in the home (the "Share Acquisition"). This strategic acquisition aligns with the Company's commitment to enhancing its portfolio in the healthcare tech

    12/5/25 4:05:00 PM ET
    $PTHL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Pheton Holdings Ltd Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

    Beijing, China, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Pheton Holdings Ltd (NASDAQ:PTHL) (the "Company"), a healthcare solution provider specializing in treatment planning systems for brachytherapy and other related products and services, today announced, on October 20, 2025, the Company received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that based on the closing bid price of the Class A ordinary shares of the Company for the last 30 consecutive business days, the Company no longer meets the continued listing requirement of Nasdaq under Nasdaq Listing Rules 5550(a)(2), to maintain a minimum bid price of $1 per share. Th

    10/23/25 4:15:00 PM ET
    $PTHL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care